Pfizer Animal Health’s canine Porphyromonas vaccine has been discontinued, effective early April 2011, due to efficacy issues. The product was designed as an aid to preventing periodontitis.
The Porphyromonas Denticanis-Gulae-Salivosa Bacterin vaccine was conditionally licensed by the U.S. Department of Agriculture in September 2006. Since then, the Madison, N.J.-based company has conducted a 48-month field efficacy study intended to support the full licensure of this product.
Although the study confirmed the vaccine’s safety, it “did not demonstrate a vaccine effect in vaccinates (as compared to controls) for either of the key efficacy variables assessed (attachment loss and gingival bleeding index),” according to a letter sent to veterinarians in early March by Oliver Knesl, BVSc, MRCVS, marketing manager of companion animal biologicals at Pfizer Animal Health.
On the basis of these results, Pfizer Animal Health will not pursue renewal of the current conditional license for the vaccine, Sherry Podhayny, VMD, told Veterinary Practice News. Dr. Podhayny is the manager of veterinary operations of companion animal biologicals at Pfizer Animal Health.
Any product still in inventory can continue to be administered safely until product expiration, she said. The company has produced a pet owner communication tear sheet. The sheet gives further details about the study and offers other options for keeping dog’s teeth and gums healthy.